11 Results for "

SPDB-DM4

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "SPDB-DM4" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-132258A
CAS No.: 1453084-37-1
Purity:  99.71%
Synonyms: IMGN853 (solution)
Research Areas:  

Cancer

Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-12460
CAS No.: 1626359-62-3
Purity:  98.14%
Research Areas:  

Cancer

SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-101141
CAS No.: 1626359-59-8
Purity:  99.81%
Research Areas:  

Cancer

sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99542
CAS No.: 2254086-60-5
Synonyms: SAR-408701; HuMAb2-3-SPDB-DM4
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
loading...
    loading...
Cat. No.: HY-164669
Research Areas:  

Cancer

ADC Control Human IgG1-DM4 is an isotype control of ADC Human IgG1-DM4. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is SPDB-DM4 (HY-12460).
loading...
    loading...
Cat. No.: HY-150363
ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141) .
loading...
    loading...
Cat. No.: HY-141596
CAS No.: 1280215-91-9
Purity:  99.81%
Research Areas:  

Cancer

Lys-Nε-SPDB-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody agent conjugate (ADC) .
loading...
    loading...
Cat. No.: HY-171681
Anti-CCL2 (Carlumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with the linker SPDB (HY-12448) and the tubulin inhibitor DM4 (HY-12454). The ADC toxic molecule and linker part are sulfo-SPDB-DM4 (HY-101141). Anti-CCL2 (Carlumab)-SPDB-DM4 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-171736
Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated with the linker SPDB (HY-12448) and the tubulin inhibitor DM4 (HY-12454). The ADC toxic molecule and linker part are sulfo-SPDB-DM4 (HY-101141). Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-101141R
CAS No.: 1626359-59-8
sulfo-SPDB-DM4 (Standard) is the analytical standard of sulfo-SPDB-DM4 (HY-101141). This product is intended for research and analytical applications. sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
loading...
    loading...
Cat. No.: HY-185718
Trastuzumab-DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab (HY-P9907) with DM4 (sulfo-SPDB-DM4) (HY-101141) via a cleavable linker. DM4 is a tubulin inhibitor that suppresses cell division. Trastuzumab-DM4 significantly inhibits tumor growth in Trastuzumab-resistant HER2 xenograft tumor models. Trastuzumab-DM4 can be used for the research of HER2-positive breast cancer .
loading...
    loading...
  • 1